Indolylmaleimide derivatives

Details for Australian Patent Application No. 2005205182 (hide)

Owner Novartis AG

Inventors Von Matt, Peter; Evenou, Jean-Pierre; Van Eis, Maurice; Wagner, Jurgen

Agent Davies Collison Cave

Pub. Number AU-B-2005205182

PCT Pub. Number WO2005/068454

Priority 0401090.6 19.01.04 GB; 0401089.8 19.01.04 GB

Filing date 19 January 2005

Wipo publication date 28 July 2005

Acceptance publication date 16 July 2009

International Classifications

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 403/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

20 July 2006 PCT application entered the National Phase

  PCT publication WO2005/068454 Priority application(s): WO2005/068454

16 July 2009 Application Accepted

  Published as AU-B-2005205182

12 November 2009 Standard Patent Sealed

12 August 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005205183-Indolylmaleimide derivatives as PKC inhibitors

2005205181-Particle-induced ghrelin immune response